How do you find an investor for a biotech company that reverses damages of aging at a cellular level (requires 100 million)?

The first thing you need is a story. The story has many chapters – about technology, about your team, about clinical utility, about intellectual property, about risks – but it has to have a certain ending. That ending is one in which investors make a 10X return on their investment. At least. Few early-stage investors Read More …

Is it true that drug price regulation would be as bad as Mao’s Great Leap Forward?

“True” is far too strong a word. But the estimate is neither ridiculous nor a troll, despite the use of such an inflammatory comparator. The argument is simple – a cited RAND study estimates the disincentivization to pharma R&D of drug price regulation would end up costing the average North American or European of ages 55–65 about 0.7 year Read More …

How does CancerSEEK compare to other liquid biopsies?

This work[1] blows away previous efforts. The word “breakthrough” is used far too often to describe results that are incremental, or that are promising but not well-supported. CancerSEEK is a genuine breakthrough. The gold standard for cancer diagnosis is the biopsy – a bit of suspect tissue is excised and studied, and determined to be benign Read More …

How is Trump reducing the cost of drugs?

He’s reducing the cost of drugs the same way he is responding to the opioid epidemic: by saying whatever sounds good at the moment and then ignoring the problem. As with all policy issues that require more than a tweet, Trump will simply follow the lead of the Republicans in Congress. So the real question is what Read More …